superoxide dismutase/悪性腫瘍

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable BACKGROUND OF THE INVENTION Cancer is the second leading cause of death behind heart disease. In fact, cancer incidence and death figures account for about 10% of the U.S. population in certain

PRIORITY This application corresponds to the national phase of International Application No. PCT/EP2012/061393 filed Jun. 15, 2012 which, in turn, claims priority to European Patent Application No. 11.170076.1 filed Jun. 16, 2011, the contents of which are incorporated by reference herein in their

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a 371 of PCT/EP2014/073597, filed Nov. 3, 2014, which claims the benefit of both Italian Patent Application No. RM2013A000608 filed Nov. 4, 2013 and European Patent Application 14178505.5 filed Jul. 25, 2014. FIELD OF THE INVENTION The

TECHNICAL FIELD The present invention relates to a copper complex for treating cancer by decreasing tumor growth, increasing survival of a host, decreasing tumor metastasis and inducing morphological differentiation of cancerous cells. A method for treatment of cancer using this complex is also

BACKGROUND OF THE INVENTION This invention relates to a diagnostic test drug comprising monoclonal antibody to human copper.zinc-superoxide dismutase and a diagnostic test method using the same, and more specifically to a diagnostic test drug comprising monoclonal antibody to human

TECHNICAL FIELD The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The

BACKGROUND OF THE INVENTION This invention relates to a monoclonal antibody having high specificity against human manganese-superoxide dismutase (hereinafter abbreviated as human Mn-SOD), a method for producing the monoclonal antibody, an assay reagent or assay kit and assay method by use thereof,

CROSS-REFERENCE TO RELATED APPLICATIONS This is a 371 of PCT/EP2003/009229, filed 20 Aug. 2003 which claims priority from German Patent Application No. 102 38 046.5 filed 20 Aug. 2002. TECHNICAL FIELD The present invention relates to a method for investigating body fluids for cancer cells, the use

TECHNICAL FIELD This invention relates to siRNA molecules, and more particularly to MnSOD siRNA molecules. BACKGROUND MnSOD plays an important role in protecting cells from injury due to oxidative stress, and is essential for aerobic life. MnSOD catalyzes the conversion of superoxide (O.sub.2.sup.-)

SEQUENCE LISTING This application contains a Sequence Listing electronically submitted via EFS-web to the United States Patent and Trademark Office as a text file named "Sequence_Listing.txt." The electronically filed Sequence Listing serves as both the paper copy required by 37 C.F.R.

FIELD OF THE INVENTION The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexins, leptin, antibodies and the like, cytokines and chemokines,

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a 371 National based on International Application No. PCT/US2009/045029, filed on May 22, 2009, which claims priority to U.S. Provisional Application No. 61/055,418, filed May 22, 2008. Each of these applications is incorporated by